#Alzheimer's

Lead report

Biogen Acquires RayThera for Up to $1 Billion: Strategic Expansion in Neuroscience

Biogen has agreed to acquire privately held biotech RayThera for up to $1 billion, gaining a preclinical candidate targeting Alzheimer's and other neurodegenerative diseases. The deal underscores Biogen's deepening commitment to neuroscience.